<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03841812</url>
  </required_header>
  <id_info>
    <org_study_id>CINI-ZYLX-201809-50</org_study_id>
    <nct_id>NCT03841812</nct_id>
  </id_info>
  <brief_title>Comparation Analgesia Efficiency With Propofol Combine Sevoflurane vs Propofol</brief_title>
  <official_title>Comparation Analgesia Efficiency With Propofol Combine Sevoflurane vs Propofol Using Index of Nociception (NOX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China International Neuroscience Institution</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China International Neuroscience Institution</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study purpose to compare analgesia efficiency of propofol combine with sevoflurane with&#xD;
      propofol only using index of Nociception (NOX)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Recently study found sevoflurane plays an important role through spinal nerve peptide&#xD;
           receptor (NK.1R), glycine receptor (GlyR), neuron nicotinic receptor (nnAChRs),&#xD;
           Methyl-1-methyl-1-day aspartate (NMDA receptor), and TRPV1 receptor (TRPV1 receptor)&#xD;
           produce the analgesic efficiency.&#xD;
&#xD;
        2. propofol was traditional sedation reagent.&#xD;
&#xD;
        3. index of Nociception (NOX) was the objective index for analgesia This study purpose to&#xD;
           compare analgesia efficiency of Only Propofol and sevoflurane combine with propofol&#xD;
           using index of Nociception (NOX)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Actual">July 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>qNOX change</measure>
    <time_frame>during operation</time_frame>
    <description>Nociception of index (qNOX) difference between two groups. The nociception index (NOX) derived from electroencephalogram (EEG) signals has been proposed as a noninvasive guide to indicate anesthesia depth. The neurological processing of noxious stimuli is defined as nociception. NOX ranges from 0-99, and the lower the index, the deeper the state of analgesia. NOX lower than 20 represents deep analgesia, and higher than 80 represents inadequate analgesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PACU duration</measure>
    <time_frame>24 hours</time_frame>
    <description>Post anesthesia care unit duration(PACU duration). The longer PACU duration indicate the worse situation of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PONV difference between two groups</measure>
    <time_frame>24 hours</time_frame>
    <description>postoperative nausea and vomiting ratio(PONV) difference between two groups. The more frequency of PONV, the worst comfortable outcome of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post- operative pain difference between two groups</measure>
    <time_frame>24 hours</time_frame>
    <description>Post- operative pain difference between two groups using VAS(Visual analogue rating) Score evaluation. Pain was assessed 24 h post operation using a 0-10 numeric pain rating scale (VAS scale), where zero meant no pain and 10 meant the worst imaginable pain.VAS score (Post-operation 24 h) (0-1 VAS indicate None pain; 2-5 VAS indicate Moderate pain; 6-10 VAS indicate severe pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Nociceptive Pain</condition>
  <condition>Analgesic Adverse Reaction</condition>
  <condition>Inhalant Use</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg/kg/h Propofol continue infusion during the maintain of anesthesia during the maintain of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol &amp; Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/kg/h Propofol &amp; 1% Sevoflurane group continue infusion(Balance anesthesia) during the maintain of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5mg/kg/h Propofol</intervention_name>
    <description>5mg/kg/h Propofol continuously infused during intre-operation</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>5mg/kg/h Propofol Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>1% Sevoflurane continuously using during intre-operation.</description>
    <arm_group_label>Propofol &amp; Sevoflurane</arm_group_label>
    <other_name>1% Sevoflurane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 mg/kg/h Propofol</intervention_name>
    <description>2mg/kg/h Propofol continuously infused during intre-operation</description>
    <arm_group_label>Propofol &amp; Sevoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants were aged 18-65 years old,&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status I, II or III&#xD;
&#xD;
          -  scheduled to have urological surgery(would last longer than 1 h)&#xD;
&#xD;
          -  requiring general anesthesia.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  refused to participate in this study;&#xD;
&#xD;
          -  Unable to communicate normally because of consciousness alterations;&#xD;
&#xD;
          -  a history of allergy to opioids&#xD;
&#xD;
          -  contraindications to inhalational anesthesia&#xD;
&#xD;
          -  a family history of malignant hyperthermia&#xD;
&#xD;
          -  a history of alcohol or drug abuse&#xD;
&#xD;
          -  received central nervous system-active drugs&#xD;
&#xD;
          -  super obese as defined by a body mass index â‰¥40 kg/m2&#xD;
&#xD;
          -  conditions liable to alter the pharmacokinetic and pharmacodynamic behaviors of the&#xD;
             intravenous and inhalation anesthetics&#xD;
&#xD;
          -  previous head injury&#xD;
&#xD;
          -  neurologic&#xD;
&#xD;
          -  psychiatric disease&#xD;
&#xD;
          -  any disabling central nervous&#xD;
&#xD;
          -  cerebrovascular disease&#xD;
&#xD;
          -  using psychoactive&#xD;
&#xD;
          -  anti-convulsive medications at the time&#xD;
&#xD;
          -  unstable angina&#xD;
&#xD;
          -  manifested congestive heart failure&#xD;
&#xD;
          -  expected difficulty airway management&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ke Huang, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>October 10, 2020</last_update_submitted>
  <last_update_submitted_qc>October 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nociceptive Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

